276 related articles for article (PubMed ID: 30977683)
1. Rucaparib in the landscape of PARP inhibition in ovarian cancer.
Colomba E; Pautier P; Pommeret F; Leary A
Expert Rev Anticancer Ther; 2019 Jun; 19(6):437-446. PubMed ID: 30977683
[No Abstract] [Full Text] [Related]
2. How safe is rucaparib in ovarian cancer?
Cosgrove CM; O'Malley DM
Expert Opin Drug Saf; 2018 Dec; 17(12):1249-1255. PubMed ID: 30449210
[No Abstract] [Full Text] [Related]
3. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use.
Walsh C
Minerva Ginecol; 2018 Apr; 70(2):150-170. PubMed ID: 28994564
[TBL] [Abstract][Full Text] [Related]
5. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
[TBL] [Abstract][Full Text] [Related]
6. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
Dal Molin GZ; Westin SN; Coleman RL
Future Oncol; 2018 Dec; 14(30):3101-3110. PubMed ID: 30105925
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Cook SA; Tinker AV
BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
[TBL] [Abstract][Full Text] [Related]
8. Rucaparib: a new treatment option for ovarian cancer.
Sabatucci I; Maltese G; Lepori S; Tripodi E; Bogani G; Lorusso D
Expert Opin Pharmacother; 2018 May; 19(7):765-771. PubMed ID: 29672168
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
Della Corte L; Foreste V; Di Filippo C; Giampaolino P; Bifulco G
Expert Opin Investig Drugs; 2021 May; 30(5):543-554. PubMed ID: 33724122
[TBL] [Abstract][Full Text] [Related]
11. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
Kurnit KC; Avila M; Hinchcliff EM; Coleman RL; Westin SN
Pharmacol Ther; 2020 Sep; 213():107588. PubMed ID: 32450190
[TBL] [Abstract][Full Text] [Related]
13. A profile on the FoundationFocus CDxBRCA tests.
Ford L; Wolford JE; Brown SM; Randall LM
Expert Rev Mol Diagn; 2020 Mar; 20(3):285-292. PubMed ID: 32028808
[No Abstract] [Full Text] [Related]
14. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Lee EK; Matulonis UA
Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
[TBL] [Abstract][Full Text] [Related]
15. Veliparib: a new therapeutic option in ovarian cancer?
Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
[TBL] [Abstract][Full Text] [Related]
16. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
Mirza MR; Pignata S; Ledermann JA
Ann Oncol; 2018 Jun; 29(6):1366-1376. PubMed ID: 29750420
[TBL] [Abstract][Full Text] [Related]
17. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.
Drew Y; Kristeleit RS; Oaknin A; Ray-Coquard I; Haris NM; Swisher EM
Oncologist; 2020 Jan; 25(1):e109-e119. PubMed ID: 31575788
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors in ovarian cancer.
Ledermann JA
Ann Oncol; 2016 Apr; 27 Suppl 1():i40-i44. PubMed ID: 27141070
[TBL] [Abstract][Full Text] [Related]
19. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies.
Bahena-González A; Toledo-Leyva A; Gallardo-Rincón D
Chin Clin Oncol; 2020 Aug; 9(4):51. PubMed ID: 32819110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
